Tag Archive for: antibody-drug conjugate
Phase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Potential Treatment For Early Prostate Cancer: TGW101
/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by MaxNext-Generation ADCs for Cancer Treatment with Potential in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxSDV2102: A Promising ADC That Targets PSMA Expressing Tumors
/in Antibody-Drug Conjugate, Preclinical Research/by MaxTD001: a New Potent ADC for Prostate Cancer Expressing PSMA
/in Antibody-Drug Conjugate, Preclinical Research/by MaxPhase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxFG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/in Clinical Trial, Metastatic, Phase 2/by MaxBR111: A New ADC Therapy That Could Work Also For Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxPhase 1 Trial: CRB-701, A Promising Antibody-Drug Conjugate Targeting Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026
- Phase 1 Trial: IL‑18–Armored STEAP1 CAR T Cells for Metastatic Castration‑Resistant Prostate Cancer September 7, 2026
- Newsletter 36/2026 September 6, 2026